Effect of silencing lncRNATUG1 on rapamycin-induced inhibition of endothelial cell proliferation and migration

XUE GAO¹, TAO ZHANG¹, XI-YUN ZENG¹, GUO-JIAN LI², LING-JUAN DU², ZHEN-HUAN MA², JIA WAN² and YONG YANG²

¹Department of Geriatric Disease, The First Hospital of Kunming, Kunming, Yunnan 650011; ²Department of Vascular Surgery, The Fourth Affiliated Hospital, Kunming Medical University, The Second People's Hospital of Yunnan Province, Kunming, Yunnan 650021, P.R. China

Received January 14, 2018; Accepted May 17, 2018

DOI: 10.3892/etm.2018.6352

Abstract. Angiogenesis refers to the formation of new blood vessels from existing blood vessels. The proliferation and migration of endothelial cells serves a key function in this process. Previous research has demonstrated that rapamycin suppresses endothelial cell proliferation and migration, as well as angiogenesis. However, the mechanism by which rapamycin inhibits the proliferation and migration of endothelial cells remains unclear. Long noncoding RNAs (lncRNAs) serve a key function in the regulation of endothelial cell function. The aim of the current study was to investigate whether lncRNA taurine upregulated 1 (lncRNATUG1) is involved in rapamycin-induced inhibition of proliferation and migration in human umbilical vein endothelial cells (HUVECs). Reverse transcription quantitative polymerase chain reaction results indicated that the expression of lncRNATUG1 was upregulated in HUVECs that had been cultured with rapamycin. Subsequently, HUVECs were transfected with siRNAs and CCK-8 assays were performed to detect cell proliferation; additionally, flow cytometry was employed to detect cell apoptosis, and wound healing assays were performed to investigate cell migration. The results demonstrated that rapamycin suppressed the proliferation and migration of HUVECs, and promoted the apoptosis of HUVECs. In addition, rapamycin downregulated the expression of vascular endothelial growth factor (VEGF), matrix metalloproteinase (MMP)-2 and MMP-9 in HUVECs. However, silencing of lncRNATUG1 was revealed to attenuate rapamycin-induced inhibition of cellular proliferation and migration of HUVECs, as well as upregulating the expression of VEGF, MMP2 and MMP-9. These results suggested that lncRNATUG1 regulates rapamycin-induced inhibition of endothelial cell proliferation and migration. Therefore, lncRNATUG1 may serve a key function in rapamycin-induced inhibition of endothelial cell proliferation and migration.

Introduction

Endothelial cells are an important feature of blood vessels, and dysfunction of vascular endothelial cell proliferation and migration may result in the development of various vascular diseases, including atherosclerosis, as well as neointimal proliferation associated with vein graft failure and in-stent restenosis. Therefore, the proliferation and migration of vascular endothelial cells serves a key function in vascular diseases, and an understanding of the associated underlying mechanisms is of critical importance.

Long non-coding RNAs (lncRNAs) are defined as transcripts of >200 nucleotides in length that do not encode for proteins. Initially, lncRNAs were considered to be a transcription ‘noise’, and to not have biological function (1). However, numerous studies have suggested that lncRNAs serve key functions in the regulation of cell development, differentiation, proliferation, migration and apoptosis, as well as other endothelial cell functions and the pathogenesis of cardiovascular diseases (2-7). At present, a number of studies have indicated that certain lncRNAs are involved in the development of cardiovascular disease via the regulation of endothelial cell proliferation, migration and apoptosis. For example, Michalik et al (8) demonstrated that lncRNA metastasis-associated lung adenocarcinoma transcript-1 (lncRNAMALAT1) is involved in the regulation of endothelial cell function and vascular growth. In diabetic rats, the downregulation of lncRNAMALAT1 has been revealed to inhibit cardiac myocyte apoptosis and attenuate left ventricular function (9), as well as suppress the proliferation and migration of retinal endothelial cells, and attenuate retinal vascular injury inflammation and function (10). Tao et al (11) demonstrated that downregulation of lncRNAH19 inhibits the proliferation of cardiac fibroblasts. Pan (12) revealed that lncRNAH19 regulates the proliferation and apoptosis of human umbilical vein endothelial cells...
(HUVECs) and vascular smooth muscle cells (VSMCs) via modulation of the mitogen-activated protein kinase and nuclear factor-κB signaling pathways, which subsequently regulate atherosclerosis formation. Ballantyne et al (13) demonstrated that smooth muscle enriched lncRNA is involved in regulating the proliferation of VSMCs and is highly expressed in atherosclerotic plaques. Furthermore, Qiu et al (14) revealed that silencing the expression of lncRNA maternally expressed gene 3 (lncRNA-MEG3) promotes endothelial cell proliferation and angiogenesis; and upregulation of the expression of lncRNA-MEG3 suppresses angiogenesis and the cell cycle in endothelial cells. These results indicate that lncRNAs serve key functions in the regulation of endothelial cell function.

Taurine upregulated 1 (TUG1), a 7.1-kb lncRNA, was first identified in the retinal cells of newborn mice and has been demonstrated to serve a key function in retinal development (15). Previous studies have revealed that lncRNA TUG1 is involved in the development of tumors via regulation of tumor cell proliferation and migration. Furthermore, TUG1 is highly expressed in vascular endothelial cells (16,17). Yin et al (6) demonstrated that lncRNA TUG1 is highly expressed in the mouse pancreas and downregulates the expression of TUG1, which subsequently affects the apoptosis and insulin secretion of pancreatic β cells, thus suggesting that lncRNA TUG1 may represent a new target for the treatment of diabetes. However, little is known about the association between TUG1 and vascular diseases. Therefore, investigation into the role of TUG1 is important with regards to vascular endothelial cells and vascular diseases.

Rapamycin is a potent immunosuppressive agent, which is able to inhibit the proliferation and migration of endothelial cells and angiogenesis. Rosner et al (18) identified that rapamycin inhibits human in-stent restenosis by inhibiting the proliferation and migration of vascular smooth muscle cells. Kawatsu et al (19) identified that rapamycin inhibits autologous vein graft restenosis by impeding venous neointimal hyperplasia. Although treatment with rapamycin reduces the incidence of postoperative restenosis by inhibiting the proliferation and migration of vascular smooth muscle cells, it increases the incidence of thrombosis. However, although certain drugs may be used to treat the occurrence of thrombus, they may be non-responsive and exhibit an efficacy that is below expectations (20-23). To date, the mechanism by which rapamycin inhibits the proliferation and migration of endothelial cells has been studied (24); however, the underlying mechanisms remain unclear. Recent research has revealed that lncRNAs serve key functions in the regulation of cell proliferation and migration. Li et al (25) reported that the lncRNA HOX transcript antisense intergenic RNA regulates the AKT/mammalian target of rapamycin (mTOR) signaling pathway, which subsequently enhances osteosarcoma cell proliferation and metastasis. Wang et al (26) demonstrated that lncRNA colorectal neoplasia differentially expressed promotes the proliferation and invasion of glioma cells by regulating the mTOR pathway. Matsumoto et al (27) demonstrated that the polycode encoded by LIN00961 serves a key function in regulating mTOR complex 1 activity. These results indicate that lncRNAs may be involved in regulating the function of endothelial cells treated with rapamycin. Therefore, it is important to determine the underlying molecular mechanism associated with inhibition of the proliferation and migration of rapamycin-treated vascular endothelial cells. The current study aimed to investigate the effect of rapamycin on the proliferation, migration and apoptosis of endothelial cells, as well as to investigate the association of lncRNA TUG1 with these processes.

Materials and methods

Cell culture. Human umbilical vein endothelial cells (HUVECs; cat. no. CRL-1730) were purchased from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). HUVECs were cultured in Dulbecco's modified Eagle's medium (DMEM; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% fetal bovine serum (FBS; Thermo Fisher Scientific, Inc.) and 10 ng/ml vascular endothelial growth factor (VEGF; PeproTech, Inc., Rocky Hill, NJ, USA) at 37˚C in 5% CO2. All experiments were performed according to the manufacturer's protocol.

Small-interfering RNA (siRNA) and cell transfection. siRNA specifically targeting TUG1 (siTUG1: siTUG1-1, 5'-GCU UGG CUUCUAUUCUGAAUCCUU-3'; siTUG1-2, 5'-CAGCUG UUACCAUCAACUUUA-3') and negative control siRNA (siNC, 5'-UUCUCGAAGUGUACAGUTT-3') were purchased from Shanghai GenePharma Co., Ltd. (Shanghai, China). Once HUVECs reached 50-70% confluence, they were seeded in 6-well plates and transfected with 100 nM siTUG1 and siNC using Lipofectamine® 2000 (Invitrogen; Thermo Fisher Scientific, Inc.), according to the manufacturer's protocol. At 24 h post-transfection, DMEM and 100 ng/ml rapamycin (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) were added. Subsequently, the cells were harvested for reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and western blot analysis.

RT-qPCR. Total RNA was extracted from cells using RNAiso Plus reagent (Takara Biotechnology Co., Ltd., Dalian, China) according to the manufacturer's protocol. cDNA was synthesized from the extracted RNA using the Fast Quant RT kit (Tiangen Biotech Co., Ltd., Beijing, China) according to the ABI 7500 qPCR system (Applied Biosystems; Thermo Fisher Scientific, Inc.). The thermocycling conditions used for qPCR were as follows: 95˚C for 5 min, followed by 40 cycles of 95˚C for 15 sec and 60˚C for 1 min. The sequences of primers used for qPCR were as follows: TUG1 forward, 5'-TCCAGAGCCTCAGTGCAAAC-3' and reverse, 5'-TGGTGTGTTGTGTGATGGC-3'; VEGF forward, 5'-CTACCTCCACCATGCACACGT-3' and reverse, 5'-GGCAGTACGTGCGAGTGA-3'; matrix metalloproteinase (MMP)-2 forward, 5'-TGTAGGGCATCGTCAGATCC-3' and reverse, 5'-GGGCTCTGATACCGGATCTCAA-3'; MMP-9 forward, 5'-GTCATCCAGTTGTTGTCGC-3' and reverse, 5'-GGGACCAACTGTCATCCTG-3'; B-cell lymphoma 2 (Bcl-2) forward, 5'-TGGTGTGGAGAAGGTCTAC-3' and reverse, 5'-GCGCGTGAGTTCCA-3'; Caspase3 forward, 5'-ATGGAAACGGCAAATCAATTGAC-3' and reverse, 5'-GTGTCATGCAATCATTGCC-3' and GAPDH forward, 5'-TCTCTGCTCCCTCCTGTTCA-3' and reverse, 5'-CAGTCTCAGGACACACATG-3'.
reverse, 5'-GGCCCAATACGACCAAATC-3'. GAPDH was used as an internal control. The relative gene expression levels were determined using the 2^{ΔΔCq} method (28).

**Cell proliferation assay.** A total of ~1x10^5 HUVECs were seeded into 96-well plates and subsequently incubated for 24 h at 37°C in 5% CO₂. Once the cells reached a confluence of 70%, they were transfected with siTUG1-1 and siNC using Lipofectamine™ 2000, according to the manufacturer's protocol. At 24 h post-transfection, DMEM with or without 100 ng/ml rapamycin was added to the cells and subsequently incubated with 10 µl of CCK-8 reagent (Dojindo Molecular Technologies, Inc., Kumamoto, Japan) was added to each well at 24, 48 and 72 h time intervals. The cells were then incubated at 37°C for 4 h. The absorbance was measured at 450 nm with an EnVision® Multi-Mode Plate Reader (PerkinElmer, Inc., Waltham, MA, USA).

**Cell apoptosis analysis.** Cell apoptosis was determined using an Annexin V-FITC/PI Apoptosis kit [MultiSciences (Lianke) Biotech Co., Ltd, Hangzhou, China]. Then, the cells were harvested by trypsinization without EDTA via centrifugation at 300 x g for 5 min at 4°C. Cells (1x10^6 cells/ml) were then washed twice with cold PBS and subsequently incubated with 500 µl of Annexin V-FITC and 10 µl PI staining solution for 15 min at room temperature in the dark. Apoptosis was then determined using a BD FACSCalibur flow cytometer (BD Biosciences, San Jose, CA, USA). The absorbance was measured at 450 nm with an EnVision® Multi-Mode Plate Reader (PerkinElmer, Inc., Waltham, MA, USA). Data are presented as the mean ± standard deviation. Each experiment was repeated ≥3 times and differences between two groups were statistically analyzed using a Student's t-test. Differences among groups were statistically analyzed using one-way analysis of variance followed by a Tukey's post-hoc test. P<0.05 was considered to indicate a statistically significant difference.

**Results**

**Expression of IncRNA-TUG1 is upregulated in HUVECs incubated with rapamycin.** Following incubation of HUVECs with 100 ng/ml rapamycin for 24 h, the RT-qPCR results indicated that expression of IncRNA-TUG1 was significantly upregulated compared with the control group (P<0.01; Fig. 1).

**Rapamycin induces cell apoptosis in HUVECs.** In order to investigate the effect of rapamycin on cell apoptosis, HUVECs were treated with 100 ng/ml rapamycin for 24 h. The results indicated that rapamycin significantly increased HUVEC apoptosis (P<0.01; Fig. 2A). Additionally, Bcl-2 expression was decreased, whereas the expression of Caspase3 was increased, following rapamycin treatment (P<0.01; Fig. 2B and C).

**Rapamycin inhibits cell proliferation and migration in HUVECs.** The effects of rapamycin on the proliferation and migration of HUVECs were determined using a CCK-8 assay and an artificial wound healing assay, respectively. The results showed that rapamycin significantly inhibited cell proliferation and migration (P<0.01; Fig. 2B and C).

**Figure 1. Expression of TUG1 is upregulated in human umbilical vein endothelial cells incubated with RAPA. **P<0.01. TUG1, taurine upregulated 1 (non-protein coding); RAPA, rapamycin.
migration of HUVECs were investigated using CCK-8 and cell scratch assays, respectively. The results indicated that rapamycin inhibited cell proliferation (P<0.01; Fig. 3A) and migration (Fig. 3B). In addition, the levels of VEGF, MMP-2 and MMP-9 were significantly decreased following treatment with rapamycin (P<0.01; Fig. 3C and D).

Expression levels of lncRNATUG1 in HUVECs are decreased following transfection. In order to downregulate the expression of lncRNATUG1, lncRNATUG1 siRNAs were transfected into HUVECs. The results of RT-qPCR analysis indicated that siTUG1-1 and siTUG1-2 significantly inhibited the expression of lncRNATUG1 in HUVECs (P<0.01; Fig. 4A); however, siTUG1-1 demonstrated a greater knockdown efficiency compared with siTUG1-2. Therefore, siTUG1-1 was selected for use in subsequent experiments.

Silencing of lncRNATUG1 attenuates rapamycin-induced inhibition of HUVEC proliferation and migration. To investigate the effect of silencing lncRNATUG1 expression on the rapamycin-induced inhibition of HUVEC proliferative ability, a CCK-8 assay was performed. Following transfection, cells were treated with 100 ng/ml rapamycin for 24, 48 and 72 h. The results indicated that suppression of lncRNATUG1 expression promoted the proliferation of HUVECs compared with the negative control (P<0.01; Fig. 5A). Additionally, subsequent wound healing analysis indicated that downregulation of lncRNATUG1 expression increased the migration ability of HUVECs compared with the negative control (Fig. 5B). Furthermore, the results of RT-qPCR and western blot analyses indicated that silencing of lncRNATUG1 significantly upregulated the expression levels of MMP-2 (P<0.01), MMP-9 (P<0.05 for mRNA expression, P<0.01 for protein expression) and VEGF (P<0.01 for mRNA expression, P<0.05 for protein expression; Fig. 5C and D) compared with the negative control. These results suggested that lncRNATUG1 may regulate rapamycin-induced inhibition of HUVEC proliferation and migration.

Silencing of lncRNATUG1 attenuates rapamycin-induced inhibition of HUVEC apoptosis. To investigate whether silencing of lncRNATUG1 could affect rapamycin-induced apoptosis in HUVECs, transfected HUVECs were treated with 100 ng/ml rapamycin for 24 h. The results of flow cytometry analysis demonstrated that downregulation of lncRNATUG1 expression significantly suppressed rapamycin-induced apoptosis in HUVECs compared with the negative control (P<0.01; Fig. 4B). In addition, the expression of Bcl-2 was revealed to be downregulated (P<0.01; Fig. 4C and D) following downregulation of IncRNATUG1 compared with the negative control. These results suggested that downregulation of IncRNATUG1 inhibits rapamycin-induced cell apoptosis.
Discussion

In the current study, it was demonstrated that rapamycin suppresses the proliferation and migration of HUVECs, and enhances the apoptosis of HUVECs, via the upregulation of lncRNATUG1. In addition, the expression levels of VEGF, MMP-2 and MMP-9 were indicated to be downregulated following treatment with rapamycin. The results of the present study identified that silencing lncRNATUG1 expression decreased the apoptosis of HUVECs and promoted the proliferation and migration of HUVECs treated with rapamycin; whereas the expression levels of VEGF, MMP-2 and MMP-9 were upregulated following the silencing of IncRNATUG1 expression. Furthermore, the results of the present study revealed that the effect of rapamycin on the proliferation, migration and apoptosis of HUVECs may be associated with the upregulation of IncRNATUG1 expression. Therefore, IncRNATUG1 may represent a novel target for the treatment of vascular disease.

It has been well established that the proliferation and migration of vascular endothelial cells serves a key function in angiogenesis (29,30). Previous studies have identified that...
Figure 4. Silencing of TUG1 significantly attenuates RAPA-induced apoptosis of HUVECs. (A) TUG1 expression following HUVEC transfection with siTUG1 and siNC. (B) Apoptosis of HUVECs. Expression of apoptosis-associated proteins following TUG1 silencing was evaluated at the (C) mRNA and (D) protein level. *P<0.05 vs. Control group. RAPA, rapamycin; HUVEC, human umbilical vein endothelial cell; si, small interfering RNA; TUG1, taurine upregulated 1 (non-protein coding); NC, negative control; Bcl-2, B-cell lymphoma 2.

Figure 5. Silencing of TUG1 attenuates rapamycin-induced inhibition of (A) proliferation and (B) migration of human umbilical vein endothelial cells. Magnification, x100. VEGF, MMP-2 and MMP-9 expression levels were evaluated at the (C) mRNA and (D) protein level. *P<0.05 and **P<0.01 vs. the siNC group. RAPA, rapamycin; VEGF, vascular endothelial growth factor; MMP, matrix metalloproteinase; OD, optical density; si, small interfering RNA; TUG1, taurine upregulated 1 (non-protein coding); NC, negative control.
lncRNAs are highly expressed in endothelial cells, and are involved in the development of cardiovascular diseases via regulation of the proliferation and migration of endothelial cells. For example, lncRNA-p21 regulates the formation of neo-intima, as well as the proliferation and apoptosis of VSMCs, by enhancing the transcriptional activity of P53 and inhibiting the formation of atherosclerosis. Therefore, lncRNA-21 may represent a therapeutic target for atherosclerosis and other cardiovascular diseases (31). Yan et al. (32) identified that silencing lncRNA myocardial infarction-associated transcript significantly inhibited the proliferation and migration of vascular endothelial cells and suppressed angiogenesis. Zhang et al. (33) reported that the proliferation of VMSCs was significantly inhibited following treatment with baicalein and that the expression of lncRNA-AK021954 was also significantly increased. This suggests that baicalein may inhibit the proliferation of VMSCs via regulation of lncRNA-AK021954 expression.

To date, few studies have investigated lncRNA-TUG1 with regards to vascular disease, having instead predominantly focused on the study of lncRNA-TUG1 in the context of tumorigenesis. Previous studies have indicated that silencing of lncRNA-TUG1 affects the proliferation and migration of tumor cells, which subsequently inhibits the formation of tumor blood vessels (34,35). Zhao et al. (36) indicated that silencing TUG1 with siRNA inhibited proliferation and invasion, and promoted apoptosis, of glioma cells. Zhang et al. (37) revealed that downregulation of TUG1 inhibited proliferation, migration and invasion, and promoted apoptosis, of renal cell carcinoma. Han et al. (38) suggested that TUG1 was upregulated in bladder cancer, and silencing TUG1 via siRNA inhibited the proliferation and promoted apoptosis of bladder cancer cell lines. In addition, previous studies have identified that TUG1 is highly expressed in vascular endothelial cells (8,39,40). Therefore, TUG1 may be involved in the regulation of vascular endothelial cell function. Young et al. (15) demonstrated that lncRNA-TUG1 serves a key function in the development of the retina, and that silencing of lncRNA-TUG1 expression promotes retinal cell apoptosis. These studies suggest that TUG1 may serve a function in endothelial cell proliferation and migration, as well as in apoptosis. In the current study, it was revealed that, following treatment with rapamycin, silencing of lncRNA-TUG1 significantly promoted the proliferation and migration of HUVECs, as well as suppressing the apoptosis of HUVECs. Furthermore, the expression levels of VEGF, MMP-2 and MMP-9 were upregulated in HUVECs treated with rapamycin following silencing of TUG1 expression. These results indicate that lncRNA-TUG1 affects endothelial cell function and may be involved in the suppression of the proliferation and migration of HUVECs, as well as the promotion of the apoptosis of HUVECs, following treatment with rapamycin.

In conclusion, the results of the present study revealed that rapamycin suppresses the proliferation and migration of HUVECs, and enhances the apoptosis of HUVECs, via the lncRNA-TUG1 pathway. This suggests that lncRNA-TUG1 serves a key function in rapamycin-induced inhibition of endothelial cell proliferation and migration, and may represent a novel therapeutic target for the treatment of vascular stenosis. However, the exact regulatory mechanism of lncRNA-TUG1 requires further study.

Acknowledgements

Not applicable.

Funding

The present study was supported by the Health Science and Technology Project of Yunnan Province (grant nos. 2016NS188 and 2018NS0008).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

XG and YY conceived and designed the current study; XG, TZ, XZ and GL performed the experiments and analyzed the data; XG wrote the manuscript; and LD, ZM and JW assisted with performing the experiments and analyzed the data. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.
References

1. Ponting CP, Oliver PL and Reik W: Evolution and functions of long noncoding RNAs. Cell 136: 629-641, 2009.

2. Quresha IA, Matic M and Merki M: Long non-coding RNAs in nervous system function and disease. Brain Res 1338: 20-35, 2010.

3. Wapinski O and Chang HY: Long noncoding RNAs and human disease. Trends Cell Biol 21: 354-361, 2011.

4. Dinger ME, Amaral PP, Mercer TR, Pang KC, Bruce SJ, Gardiner BB, Askarian-Amiri ME, Ru K, Soldá G, Simonis C, et al: Long non-coding RNAs in mouse embryonic stem cell pluripotency and differentiation. Genome Res 18: 1433-1445, 2008.

5. Kanduri C: Long noncoding RNA and epigenetics. Adv Exp Med Biol 722: 174-195, 2015.

6. Yin DD, Zhang EL, You H, Wang N, Wang LT, Jin FY, Zhu YN, Cao CH, Zhao YQ, De W and Tang W: Down-regulation of LncRNA TUG1 affects apoptosis and insulin secretion in mouse pancreatic β cells. Cell Physiol Biochem 35: 1892-1904, 2015.

7. Chen J, Jia YS, Liu GZ, Sun Q, Zhang F, Ma S and Wang YJ: Role of LncRNA TUG1 in intervertebral disc degeneration and nucleus pulposus cells via regulating Wnt/beta-catenin signaling pathway. BiochemBiophysics Res Commun 491: 668-674, 2017.

8. Michalik KM, You X, Manavski Y, Doddaballapur A, Zörnig M, Braun T, John D, Ponomareva Y, Chen W, Uchida S, et al: Long noncoding RNA MALAT1 regulates endothelial cell function and vessel growth. Circ Res 114: 1389-1397, 2014.

9. Zhang M, Ma Z, Wang X and Zhou Z: Down-regulation of IncRNA MALAT1 reduces cardiac myocyte apoptosis and improves left ventricular function in diabetic rats. Int J Cardiol 203: 214-216, 2016.

10. Liu YJ, Yao J, Li XM, Song YC, Wang QX, Li YJ, Yan B and Jiang Q: Pathogenic role of IncRNA-MALAT1 in endothelial cell dysfunction in diabetes mellitus. Cell Death Dis 5: e1506, 2014.

11. Tao H, Cao W, Yang JJ, Shi KH, Zhou X, Liu LP and Li J: Long noncoding RNA H19 controls DUSP5/EKR1/2 axis in cardiac fibroblast proliferation and fibrosis. Cardiovasc Pathol 25: 381-389, 2016.

12. 10 Pan JX: LncRNA H19 promotes atherosclerosis by regulating MAPK and NF-kB signaling pathway. Eur Rev Med Pharmacol Sci 21: 322-328, 2017.

13. Ballantyne MD, Pinel K, Dukin R, Vesey AT, Diver L, Mackenzie R, Garcia R, Welsh P, Sattar N and Hamilton G, et al: Smooth Muscle Enriched Long Noncoding RNA (SMILR) Regulates Cell Proliferation. Circulation 133: 2050-2065, 2016.

14. Qiuz GZ, Tian W, Fu HT, Li CP and Liu B: Long noncoding RNA-MEG3 is involved in diabetes mellitus-related microvascular dysfunction. Biochem Biophysics Res Commun 471: 135-141, 2016.

15. Young TL, Matsuda T and Cepko CL: The noncoding RNA taueregulated gene 1 is required for differentiation of the murine retina. Curr Biol 15: 501-512, 2005.

16. Fan S, Yang Z, Ke Z, Huang K, Liu N, Fang X and Wang K: Down-regulation of the long non-coding RNA TUG1 is associated with cell proliferation, migration, and invasion in breast cancer. Biomed Pharmacother 95: 1636-1643, 2017.

17. Yun-Bo F, Xiao-PO L, Xiao-LI L, Guo-Long C, Pei Z and Fa-Ming T: LncRNA TUG1 is up-regulated and promotes cell proliferation in osteosarcoma. Open Med (Wars) 11: 163-167, 2016.

18. Rosner D, McCarty N and Bennett M: Rapamycin inhibits human in stem restenosis vascular smooth muscle cells independently of pRB phosphorylation and p53. Cardiovasc Res 66: 601-610, 2005.

19. Kawatsu S, Oda KY, Tabata Y and Tabayashi K: External application of rapamycin-eluting film at anastomotic sites inhibits neointimal hyperplasia in a canine model. Ann Thorac Surg 84: 560-567, 2007.

20. van der Heijden DJ, Westendorp IC, Kiemeneij F, van der Heijden WJ, Westendorp IC, Riezebos RK, Kiemeneij F, et al: Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 109: 3171-3175, 2004.

22. Gurbel PA, Bleden KP, Samara W, Yoho JA, Hayes K, Fissaha MZ and Tantry US: Clopidogrel effect on platelet reactivity in patients with stent thrombosis: Results of the CREST study. J Am Coll Cardiol 46: 1827-1832, 2005.

23. Geisler T, Langer H, Wyssmann M, Göhring K, Zürn C, Bigalke B, Stellos K, May AE and Gawaz M: Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 27: 2420-2425, 2006.

24. Moss SC, Lightell DJ Jr, Marx SO, Marks AR and Woodset TC: Rapamycin Regulates Endothelial Cell Migration Through Regulation of the Cyclin-dependent Kinase Inhibitor p27Kip1. J Biol Chem 285: 11991-11997, 2010.

25. Li E, Zhao Z, Ma B and Zhang J: Long noncoding RNA HOTAIR promotes the proliferation and metastasis of osteosarcoma cells through the AKT/mTOR signaling pathway. Exp Ther Med 14: 3153-3158, 2017.

26. Wang Y, Wang Y, Li J, Zhang Y, Yin H and Han B: CRNDE, a long-non-coding RNA, promotes glioma cell growth and invasion through mTOR signaling. Cancer Lett 367: 122-128, 2015.

27. Song Y, Pasut A, Matsumoto M, Yamashita R, Fung J, Monteleone E, Saghatelian A, Nakayama KI, Clohessy JG and Pandolfo MP: miR101 and muscle regeneration are regulated by the LINC00961-encoded SPAR polypeptide. Nature 541: 228-232, 2017.

28. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2−(ΔΔCT) method. Methods 25: 402-408, 2001.

29. Muñoz-Chápuli R, Quesada AR and Angel Medina M: Angiogenesis and signal transduction in endothelial cells. Cell Mol Life Sci 61: 2224-2243, 2004.

30. Lamalice L, Le Bourrouilh F and Huot J: Endothelial cell migration during angiogenesis. Circ Res 100: 782-794, 2007.

31. Wu G, Cai J, Han Y, Chen J, Huang ZP, Chen C, Cai Y, Huang H, Yang Y, Liu Y, et al: LncRNA-p21 Regulates Neointima Formation. Circ Res 110: 1452-1465, 2012.

32. Yan B, Yao J, Liu Y, Li XM, Wang QX, Li YJ, Tao ZF, Song YC, Chen Q and Jiang Q: IncRNA-MIAT regulates microvascular dysfunction by functioning as a competing endogenous RNA. Circ Res 116: 1143-1156, 2015.

33. Zhang Y, Ma G, Li C, Cao Z, Qie F and Xu X: Baicaleininhibits VSMC’s proliferation via regulating LncRNAAK021954 gene expression. Int J Clin Exp Med 8: 2219-22138, 2015.

34. Li J, Zhang M, An G and Ma Q: LncRNA TUG1 acts as a tumor suppressor in human glioma by promoting cell apoptosis. Exp Biol Med (Maywood) 241: 644-649, 2016.

35. Bao K, Sun X, Mao C, Guo F, Ye S, Xu J, Zou R, Chen J, Wang L, Duan P and Xue X: Upregulation of long non-coding RNA TUG1 promotes cervical cancer cell proliferation and migration. Cancer Med 6: 471-482, 2017.

36. Zhao Z, Wang B, Hao J, Man W, Chang Y, Ma S, Hu Y, Liu F and Yang J: Downregulation of the long non-coding RNA taueregulated gene 1 inhibits glioma cell proliferation and invasion and promotes apoptosis. Oncol Lett 15: 4026-4032, 2018.

37. Zhang M, Lu W, Huang YQ, Shi JZ, Wu X, Zhang XL, Jiang RZ, Cai ZM and Wu S: Downregulation of the long noncoding RNA TUG1 inhibits the proliferation, migration, invasion and promotes apoptosis of renal cell carcinoma. J Mol Histol 47: 421-428, 2016.

38. Han YH, Liu YC, Gui YT and Cai ZM: Long intergenic non-coding RNA TUG1 is overexpressed in uterine carcinoma of the bladder. J Surg Oncol 107: 555-559, 2015.

39. Cai H, Xue Y, Wang P, Wang Z, Li Z, Hu Y, Li Z, Shang X and Liu Y: The long noncoding RNA TUG1 regulates blood-tumor barrier permeability by targeting miR-144. Oncotarget 6: 19759-19779, 2015.

40. Chen C, Cheng GQ, Yang XN, Li CS, Shi R and Zhao NN: Tanshinol suppresses endothelial cell apoptosis in mice with atherosclerosis via IncRNA TUG1 up-regulating the expression of miR-26a. Am J Transl Res 8: 2981-2991, 2016.

41. Liu HT, Li F, Wang WY, Li XJ, Liu YM, Wang RA, Guo WY and Wang HC: Rapamycin inhibits endothelial cell proliferation and migration of endothelial progenitor cells. Tex Heart Inst J 37: 194-201, 2010.
42. Wang Y, Chen J, Tang W, Zhang Y and Li X: Rapamycin inhibits the proliferation of endothelial cells in hemangioma by blocking the mTOR-FABP4 pathway. Biomed Pharmacother 85: 272-279, 2017.
43. Medici D and Olsen BR: Rapamycin inhibits proliferation of hemangioma endothelial cells by reducing HIF-1-dependent expression of VEGF. PloS One 7: e42913, 2012.
44. Xue D, Zhou C, Lu H, Xu R, Xu X and He X: LncRNA GAS5 inhibits proliferation and progression of prostate cancer by targeting miR-103 through AKT/mTOR signaling pathway. Tumor Biol 37: 1-11, 2016.
45. Malakar P, Shilo A, Mogilevsky A, Stein I, Pikarsky E, Nevo Y, Benyamini H, Elgavish S, Zong X, Prasanth KV and Karni R: Long Noncoding RNA MALAT1 promotes hepatocellular carcinoma development by SRSF1 up-regulation and mTOR activation. Cancer Res 77: 1155-1167, 2017.
46. Shui X, Zhou C, Lin W, Yu Y, Feng Y and Kong J: Long non-coding RNA BCAR4 promotes chondrosarcoma cell proliferation and migration through activation of mTOR signaling pathway. Exp Biol Med (Maywood) 242: 1044-1050, 2017.